$KPTI on NASDAQ
March 06, 2024
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
March 01, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
February 22, 2024
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
February 01, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2024
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
January 03, 2024
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2023
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
December 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2023
Karyopharm to Participate at Upcoming Investor Conferences
November 06, 2023
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
November 02, 2023
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
November 02, 2023
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
October 30, 2023
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
October 26, 2023
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
October 02, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2023
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
September 05, 2023
Karyopharm to Participate at Upcoming Investor Conferences
September 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
August 02, 2023
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 26, 2023
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
July 17, 2023
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
July 05, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2023
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
June 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
Karyopharm to Participate at the Jefferies Healthcare Conference
May 23, 2023
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
May 04, 2023
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 03, 2023
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
May 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2023
Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023
April 18, 2023
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023
April 14, 2023
Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th
April 03, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2023
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023
March 08, 2023
Karyopharm to Participate at Barclays Global Healthcare Conference
March 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 21, 2023
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
February 15, 2023
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
February 09, 2023
Karyopharm to Present at SVB Securities Global Biopharma Conference
February 08, 2023
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
February 01, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2023
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
January 04, 2023
Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2022
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
- No Recent Filings Found.
